RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
Another product from the STOP-COVID consortium led by @ShrutiGkidney and @DavidLeaf9 at @JAMAInternalMed. Hypothesis-generating work. @OchsnerNephro part of team.
It is a sad state of affairs when the RCT of tocilizumab has 60 patients who got the drug, but the observational study has 433 patients who got it https://t.co/426cyKrKF1 https://t.co/3pWvtekYoi
RT @DavidLeaf9: Congrats to all the STOP-COVID Investigators on this important work! Early Treatment With Tocilizumab and Mortality Among…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @PabloRichly: ¿Reduce el tocilizumab la mortalidad en pacientes graves? Un estudio observacional sugiere que si pero no es suficiente pa…
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/FfDa1T7Rcj via @JAMAInternalMed part of @JAMANetwork
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @AnilMakam: In as a good of an observational cohort study as possible, the suggested effect size for tocilizumab is massive for critical…
¿Reduce el tocilizumab la mortalidad en pacientes graves? Un estudio observacional sugiere que si pero no es suficiente para responder la pregunta. https://t.co/KNsGfaSE2b
Great new read: #tocilizumab in people with #COVID19 admitted to #ICU. COVACTA pre-print of the prior Roche trial for reference: https://t.co/DfaN1eeLDc Nice work from a large collaboration @ajadmon @edschenck
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @AnilMakam: In as a good of an observational cohort study as possible, the suggested effect size for tocilizumab is massive for critical…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortality was 30% lower in patients treated w tocilizumab in the first 2 days of ICU admission compared to patients not treated with tocilizumab h
RT @bethlinas: Look at the NUMBER of authors on this #manuscript-#publichealth research requires collaboration & work across disciplines. T…
RT @DavidLeaf9: Congrats to all the STOP-COVID Investigators on this important work! Early Treatment With Tocilizumab and Mortality Among…
Look at the NUMBER of authors on this #manuscript-#publichealth research requires collaboration & work across disciplines. THIS is how we do #science! GREAT to see lower risk of death from #COVID19 when #tocilizumab administered in observational study.
In as a good of an observational cohort study as possible, the suggested effect size for tocilizumab is massive for critically ill patients with #COVID19: ~10% absolute benefit in 30-day mortality I'd prefer to wait for a high quality RCT since seems too
RT @NedPagliarulo: Trio of studies on use of Roche's Actemra in treating COVID-19 published in JAMA. Randomized trial in France (n=130)…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
Interesting study. However, I must say that it is a low quality of evidence to justify the efficacy of #tolicizumab without a large effect in favor of the intervention (95% CI for mortality HR greater than 0.5).
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
Hot off the press, promising tocilzumab results
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) for initiation of #tocilizumab on first 2 days after ICU admission. The hazard ratio is 0.41 in those admitted within 3 days of symptoms
Congrats to all the STOP-COVID Investigators on this important work! Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/7tuVKyhUnB via @JAMAInternalMed part of @JAMANetwork
RT @NedPagliarulo: Trio of studies on use of Roche's Actemra in treating COVID-19 published in JAMA. Randomized trial in France (n=130)…
RT @NedPagliarulo: Trio of studies on use of Roche's Actemra in treating COVID-19 published in JAMA. Randomized trial in France (n=130)…
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/7s4BDPjLkW via @JAMAInternalMed part of @JAMANetwork Using Target trial emulation, we found a 30% relative reduction in 30 day mortality in patients rec
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/TFZ75JvTx5 via @JAMAInternalMed part of @JAMANetwork @DavidLeaf9
Trio of studies on use of Roche's Actemra in treating COVID-19 published in JAMA. Randomized trial in France (n=130) https://t.co/gzFd3OPRFP Randomized trial in Italy (n=126) https://t.co/4RzZko0BaV Non-randomized, cohort study in US (n=3,924) http